[Form 4] Varex Imaging Corp Insider Trading Activity

Rhea-AI Filing Summary

Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.

Positive

• Transaction executed under a 10b5-1 trading plan, indicating pre-established, rule-compliant trading
• Full disclosure provided including shares sold, sale price, remaining beneficial ownership, and plan adoption date

Negative

• Reduction in direct ownership to 177 shares following the sale

Insights

Securities Analyst

TL;DR: Officer sold a small number of shares under a 10b5-1 plan; transaction appears routine and compliance-driven.

The sale of 3,174 shares at $12.34 per share reduces the reporting person's direct holdings to 177 shares. The filing explicitly states the trades were made pursuant to a 10b5-1 trading plan adopted on June 17, 2025, which provides an affirmative defense under Rule 10b5-1 and typically signals the trades were pre-scheduled. Given the relatively small post-transaction ownership and lack of other changes (no options or derivative activity reported), this transaction is likely immaterial to the company’s capital structure and does not by itself indicate new information about company fundamentals.

Corporate Governance Expert

TL;DR: The Form 4 documents rule-compliant insider disposal under a formal plan; governance process appears followed.

The reporting person is an officer (Chief Human Resources Officer) who executed a sale under a documented 10b5-1 plan, which typically reduces regulatory risk compared with opportunistic trading. The Form 4 discloses the quantity sold, sale price, remaining beneficial ownership, and the plan adoption date, which are the key governance disclosures investors and compliance officers look for. There is no indication of amendments or additional arrangements in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aranki Karen L

(Last) (First) (Middle)

1678 S. PIONEER ROAD

(Street)

SALT LAKE CITY UT 84104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Varex Imaging Corp [ VREX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		S		3,174	D	$12.34(1)	177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan or arrangement adopted by the reporting person on June 17, 2025.

Remarks:

	/s/ Karen L. Aranki	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Karen L. Aranki report for VREX?

Karen L. Aranki reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share.

Was the VREX sale by the officer part of a 10b5-1 plan?

Yes. The Form 4 states the sales were effected pursuant to a 10b5-1 trading plan adopted on June 17, 2025.

How many VREX shares does the reporting person own after the reported sale?

The filing reports the reporting person beneficially owned 177 shares following the transaction.

Does the Form 4 report any derivative or option transactions for VREX?

No. Table II shows no derivative securities; only a non-derivative sale of common stock is reported.

When was the Form 4 signed and filed?

The document bears the reporting person’s signature dated 09/22/2025.